Yu Zhongyang, Wang Peipei, Chen Bailin, Zhang Zihao, Jiang Jun, Zhuang Yulong
Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Fangguyuan Rd.
School of Life Sciences, Beijing University of Chinese Medicine.
Medicine (Baltimore). 2020 Nov 6;99(45):e23015. doi: 10.1097/MD.0000000000023015.
The World Health Organization announce that novel coronavirus (COVID-19) is pandemic worldwide on March 11, 2020. In this pandemic, cancer patients are prone to become critically ill after being infected with COVID-19 due to special immune conditions, and cannot effectively benefit from the treatment plan designed for normal people. However, only a few literatures report the differences between cancer patients and normal people after being infected with COVID-19. There is no systematic review to evaluate the clinical, inflammatory, and immune differences between COVID-19 patients with and without cancer. The systematic review aims to summarize and analyze the clinical, inflammatory, and immune differences between them.
We plan to conduct a systematic review according to the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines. Several databases (PubMed/MEDLINE, Embase, Web of Science, The Cochrane Library, CNKI, CBM, VIP, WanFang) were searched for relevant eligible observational studies on COVID-19 patients with cancer published from December 2019 to September 2020. Two researchers (Y.ZY and W.PP) will independently complete search strategy formulation, literature selecting, Information extraction, data collation, and quality assessment. The primary outcome will be the clinical characteristics differences between COVID-19 patients with and without cancer. Secondary outcomes will include immune function regulation characteristics such as T cell subset status, inflammation and other factors for COVID-19 patients with cancer. We intend to perform a meta-analysis of studies calculating odds ratio differences (Hedge g) for comparison in Forest plots and subgroup analysis after assessment of heterogeneity using I statistics based on compatibility on the basis of population and outcomes.
We will use the information from published researches with no need for ethical assessment. Our findings will be published in a peer-reviewed journal according to the PRISMA guidelines.
CRD42020204417.
世界卫生组织于2020年3月11日宣布新型冠状病毒（COVID-19）在全球大流行。在这场大流行中，癌症患者由于特殊的免疫状况，感染COVID-19后容易发展为重症，且无法从为正常人设计的治疗方案中有效获益。然而，仅有少数文献报道了癌症患者与正常人感染COVID-19后的差异。目前尚无系统评价来评估合并癌症与未合并癌症的COVID-19患者之间的临床、炎症及免疫差异。本系统评价旨在总结并分析两者之间的这些差异。
我们计划按照系统评价与Meta分析方案的首选报告项目（PRISMA-P）指南进行系统评价。检索多个数据库（PubMed/MEDLINE、Embase、Web of Science、Cochrane图书馆、中国知网、中国生物医学文献数据库、维普资讯、万方数据），以查找2019年12月至2020年9月发表的关于合并癌症的COVID-19患者的相关合格观察性研究。两名研究人员（Y.ZY和W.PP）将独立完成检索策略制定、文献筛选、信息提取、数据整理及质量评估。主要结局将是合并癌症与未合并癌症的COVID-19患者之间的临床特征差异。次要结局将包括合并癌症的COVID-19患者的免疫功能调节特征，如T细胞亚群状态、炎症及其他因素。我们打算在基于人群和结局的相容性使用I统计量评估异质性后，对计算比值比差异（Hedge g）的研究进行Meta分析，以便在森林图中进行比较并进行亚组分析。
我们将使用已发表研究中的信息，无需进行伦理评估。我们的研究结果将根据PRISMA指南发表在同行评审期刊上。
PROSPERO注册号：CRD42020204417。
